EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 77.14 with a ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Leads Biolabs’ LBL-024 receives Breakthrough Therapy Designation from China NMPA to treat extrapulmonary neuroendocrine carcinoma: Nanjing, China Thursday, October 10, 2024, 10: ...

Mestag Therapeutics has entered into a license and collaboration agreement with MSD (tradename of Merck & Co Inc) worth a ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by NICE as a first-line treatment for myeloma in England and ...

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Strategic Collaboration to Address Critical Healthcare Needs and Expand Access to Life-Changing Treatments ...

Traders on Thursday added to bets the Federal Reserve will deliver a 25 basis point interest-rate cut in November after a ...